Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses Janus kinase inhibitors as a promising future treatment for alopecia areata but does not present new research findings.

This study reports that tofacitinib, a JAK inhibitor, may stabilize hair loss in patients with classic lichen planopilaris and frontal fibrosing alopecia, though hair regrowth was not robust.

This study found that oral tofacitinib led to variable hair regrowth in patients with resistant alopecia areata, implying that longer treatment durations may be needed to fully assess its effectiveness.

This review discusses the role of JAK inhibitors in treating atopic dermatitis, alopecia areata, and vitiligo, highlighting their effectiveness and safety considerations but stressing the need for further research on long-term safety and patient selection.

JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.

This literature review found that Janus kinase inhibitors may help achieve remission in patients with refractory primary neutrophilic cicatricial alopecias, though data is limited to small case series and reports.

The authors highlighted promising developments in JAK inhibitors as targeted treatments for skin diseases such as atopic dermatitis, psoriasis, and alopecia areata, noting their effectiveness and safety profiles. Recent advances also suggest potential for treating melanoma with these inhibitors.

This report highlights that a coherent vision and collaboration are needed in Poland to address healthcare workforce shortages, including allowing domestic academic titles to confirm Polish language proficiency.

This study analyzed screening data from 218 alopecia areata patients before starting Janus kinase inhibitors, revealing the importance of pre-treatment screening due to risks of infections like tuberculosis and hepatitis B, with 74.8% of patients proceeding to treatment in real-world settings.

This review discusses the potential applications of JAK inhibitors in various dermatological conditions beyond atopic dermatitis, emphasizing gaps in evidence and therapeutic opportunities in the context of Chinese clinical practice, but reports no new clinical results.

This review discusses the connection between Polycystic Ovarian Syndrome and the Ayurvedic condition Pushpaghni Jatharini, proposing Ayurvedic management as a holistic approach to PCOS-related infertility, without reporting new clinical results.

This study observed that in a real-world pediatric setting, Janus kinase inhibitors led to improvements in scalp, eyebrow, and eyelash involvement in children with alopecia areata, with a generally favorable tolerability profile, though baseline imbalances and non-randomized treatment allocation limit causal conclusions and drug comparisons.

This abstract does not report results but indicates that the supplementary material includes comprehensive methodology, additional results, statistical analyses, discussion, and limitations of the Alopecia Areata Relapse Study Group's findings as presented in the main manuscript.

JAK inhibitors may reduce depression risk in alopecia areata patients.

In this study, researchers found that minoxidil sulfate enhances the anti-inflammatory effects of the JAK inhibitor baricitinib in alopecia areata, modulating inflammatory signals and preserving immune privilege features in human hair cells, which suggests potential benefits for combined therapy.

In this study, oral JAK inhibitors were found to be significantly more effective than placebo in promoting hair regrowth among adults and adolescents with moderate-to-severe alopecia areata, although they were associated with an increased risk of adverse events.

This paper reviews recent advancements in understanding hair follicle structure and the role of JAKs in hair growth, though it does not report new experimental findings.

In this study, researchers focused on the "bulge region" of hair follicles, identifying Janus kinases as key players in hair growth signaling, which could inform new therapies for hair restoration.

Baricitinib effectively stops hair loss and promotes regrowth in acute alopecia areata.

This study found that clinicians treating alopecia areata prioritize JAK inhibitor treatments with higher efficacy and faster initial hair growth, regardless of dosing frequency, and preferred the treatment option with ritlecitinib 50-mg data the least among several blinded profiles.

In this study, pediatric and young adults with alopecia areata reported high satisfaction with oral Janus kinase inhibitors, decreased hair loss severity, and a willingness to continue treatment despite potential risks, citing improvements in hair regrowth, tolerability, quality of life, and mental health.

In this case study, an 11-year-old girl with severe alopecia areata experienced complete hair regrowth and unexpected white-to-black hair repigmentation after switching from baricitinib to ritlecitinib, suggesting that prolonged Janus kinase inhibition may aid both hair and pigment restoration in severe pediatric cases.

The researchers designed a Janus microneedle system for treating vitiligo, which targets the skin’s layers to regulate the immune response, promote melanocyte regeneration, and enhance pigment transfer, offering a new precise treatment approach for this condition.

JAK inhibitors are generally safe for treating alopecia areata.

Infections and missed treatments trigger flares in alopecia areata patients on JAK inhibitors.

JAK inhibitors help regrow eyebrow and eyelash hair and improve anxiety and depression in some alopecia areata patients.

This study evaluated the use of JAK inhibitors in patients with alopecia areata episodes lasting at least eight years and found that while the overall therapeutic response was limited, a subset of patients achieved meaningful hair regrowth, suggesting these treatments as a viable option.

This review explores both traditional Ayurvedic uses and modern scientific findings on Japa Pushpa (Hibiscus rosa-sinensis), suggesting it may benefit cardiovascular health and metabolic balance as a herbal tea, but emphasizes the need for further clinical validation.

This review highlights the potential for JAK inhibitors to effectively treat inflammatory and autoimmune skin diseases by targeting the JAK-STAT signaling pathway, advocating for an integrated approach to enhance targeted therapy.